Swine as the Animal Model for Testing New Formulations of Anti-Inflammatory Drugs: Carprofen Pharmacokinetics and Bioavailability of the Intramuscular Route

dc.contributor.authorGómez, Lidia
dc.contributor.authorBoix Montañés, Antonio de Pádua
dc.contributor.authorMallandrich Miret, Mireia
dc.contributor.authorParra Coca, Alexander
dc.contributor.authorSoriano-Ruiz, José L.
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorGimeno Sandig, Álvaro
dc.contributor.authorBellido, David
dc.contributor.authorColom Codina, Helena
dc.date.accessioned2022-05-20T09:29:48Z
dc.date.available2022-05-20T09:29:48Z
dc.date.issued2022-05-12
dc.date.updated2022-05-20T09:29:48Z
dc.description.abstractAbstract Carprofen (CP) is a non-steroidal anti-inflammatory drug (NSAID) frequently used to treat respiratory diseases in numerous small animals, but also in large species. CP is a formidable candidate for further therapeutic research of human inflammatory diseases using the pig as an animal model. However, CP administration in swine is very uncommon and respective pharmacokinetics/bioavailability studies are scarce. A simultaneous population pharmacokinetic analysis after CP intravenous and intramuscular administrations in pigs has shown high extent and rate of absorption and a similar distribution profile with respect to man and other mammals. However, clearance and half-life values found in swine suggest a slower elimination process than that observed in man and some other animal species. Although not reported in other species, liver and kidney concentrations achieved at 48 h post-intramuscular administration in pigs were ten times lower than those found in plasma. Simulations pointed to 4 mg/kg every 24 h as the best dosage regimen to achieve similar therapeutic levels to those observed in other animal species. All these findings support the use of pig as an animal model to study the anti-inflammatory effects of CP in humans.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec723407
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/2445/185844
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics14051045
dc.relation.ispartofPharmaceutics, 2022, vol. 14, p. 1045
dc.relation.urihttps://doi.org/10.3390/pharmaceutics14051045
dc.rightscc-by (c) Gómez, Lidia et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationNanopartícules
dc.subject.classificationAgents antiinflamatoris
dc.subject.classificationAdministració de medicaments
dc.subject.otherNanoparticles
dc.subject.otherAntiinflammatory agents
dc.subject.otherAdministration of drugs
dc.titleSwine as the Animal Model for Testing New Formulations of Anti-Inflammatory Drugs: Carprofen Pharmacokinetics and Bioavailability of the Intramuscular Route
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
723407.pdf
Mida:
1.89 MB
Format:
Adobe Portable Document Format